Related Experiment Video
Updated: Sep 26, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
[The effects of tamoxifen on human hepatocellular carcinoma cell proliferation and transforming growth factor-beta1
Jung Woo Shin1, Young-Hwa Chung, Moo In Park
1Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Background/Aims:
Tamoxifen has been tried in patients with hepatocellular carcinoma (HCC), however, its inhibitory mechanism remains unknown. In this study, we evaluated the effects of tamoxifen on HCC cell growth and the expression of transforming growth factor-beta1 (TGF-beta1) which had been known as an important cytokine in growth of HCC.
Methods:
Hep 3B cells were cultivated in estrogen free media with 0.1 micro M, 0.5 micro M, 1 micro M, 5 micro M, and 10 micro M of tamoxifen for 6 days. Viable cells were counted daily and the TGF-beta1 concentrations in supernatant were measured by ELISA method.
Results:
The number of viable HCC cells increased rather significantly after the treatment of tamoxifen of lower concentration (0.1micro M) compared with that of the control (2.59x10(7) vs. 1.97x107; p<0.05). As the concentration of treated tamoxifen was higher, the number of viable HCC cells became gradually less, resulting in the significant decrease of it at the highest concentration (10micro M) compared with that of the control (1.40x10(7) vs. 1.97x10(7); p<0.05). TGF-beta1 concentration in supernatant of tamoxifen-treated samples was significantly decreased compared with those of controls, regardless of the amount of treated tamoxifen.
Conclusions:
These results suggest that tamoxifen may suppress TGF-beta1 expression to an extent, although it has different effects on the proliferation of HCC cells, at the various concentrations of this agent in vitro. Such effects of tamoxifen on TGF-beta1 expression may inhibit the growth and progression of HCCs over-expressing TGF-beta1 in vivo.
Insights
Tamoxifen affects hepatocellular carcinoma (HCC) cell growth differently by concentration. It suppresses transforming growth factor-beta1 (TGF-beta1) expression, potentially inhibiting HCC progression.
Area of Science:
- Hepatocellular Carcinoma Research
- Cancer Cell Biology
- Pharmacology
Context:
- Tamoxifen has been investigated for hepatocellular carcinoma (HCC) treatment.
- The precise inhibitory mechanisms of tamoxifen in HCC remain unclear.
- Transforming growth factor-beta1 (TGF-beta1) is a key cytokine implicated in HCC growth.
Purpose:
- To investigate the effects of tamoxifen on HCC cell proliferation.
- To examine the impact of tamoxifen on TGF-beta1 expression in HCC cells.
Summary:
- Tamoxifen exposure at low concentrations (0.1 micro M) increased HCC cell viability, while higher concentrations (10 micro M) significantly reduced it.
- Tamoxifen treatment consistently decreased TGF-beta1 concentrations in the supernatant across all tested concentrations.
- These findings indicate a concentration-dependent effect of tamoxifen on HCC cell growth and a general suppression of TGF-beta1.
Impact:
- Tamoxifen's differential effects on HCC cell proliferation highlight the importance of dosage.
- Suppression of TGF-beta1 by tamoxifen may offer a therapeutic strategy for HCC, particularly in tumors overexpressing TGF-beta1.
- This study provides insights into the molecular mechanisms underlying tamoxifen's action in HCC.
